树突状细胞-细胞因子诱导的杀伤细胞联合化疗治疗晚期消化道肿瘤的临床疗效  

Clinical efficacy of dendritic cells cytokine induced killer cells combined with chemotherapy in patients with advanced gastrointestinal cancer

作　　者：王仲涛[1] 王艳艳[1] 刘琳琳[1] 

机构地区：[1]辽宁省铁岭市中医医院内三科,铁岭112099

出　　处：《中国肿瘤临床与康复》2015年第2期139-141,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK)联合化疗治疗晚期消化肿瘤的临床疗效及意义。方法选取2010年3月至2011年2月间收治的100例晚期消化肿瘤患者为研究对象,采用随机抽签分组方法将患者分为观察组和对照组,每组50例。观察组患者采用DC-CIK联合化疗,所有患者均于化疗前采集外周血单个核细胞(PBMC),将其体外培养产生DC-CIK细胞,化疗结束后,输回新产生的合格的DC-CIK细胞。对照组患者则单纯采用化疗,以2周为1个疗程,观察两组患者治疗效果及1、3年生存率。结果观察组患者治疗总有效率为68.0%,明显高于对照组的42.0%,差异有统计学意义(P<0.05)。观察组患者疾病控制率为82.0%,明显高于对照组的56.0%,差异有统计学意义(P<0.05)。观察组1、3年生存率分别为92.0%和80.0%,明显高于对照组的76.0%和54.0%,差异均有统计学意义(P<0.05)。结论 DC-CIK联合化疗治疗消化道晚期肿瘤患者具有显著治疗效果,值得临床推广。Objective To investigate the clinical efficacy of dendritic cells cytokine induced killer cells combined with chemotherapy in patients with advanced gastrointestinal cancer. Methods From March2010 to February 2011,100 cases with advanced digestive cancer in Tieling Chinese Medicine Hospital were enrolled in the study. Using random draw grouping method,they were divided into observation group and control group,50 cases in each group. The observation group were treated by DC-CIK combined with chemotherapy. Peripheral blood mononuclear cells（ PBMC） were collected before chemotherapy and cultured in vitro. After chemotherapy,the generated DC-CIK cells were transferred back. The control group were treated with chemotherapy,with 2 wk as a course of treatment. The therapeutic effect of two groups and 1,3-year survival rates were observed. Results The total effective rate of the observation group was 68. 0%,significantly higher than the control group 42. 0%,with statistical significance（ P〈0. 05）; the disease control rate of the observation group was 82. 0%,significantly higher than that of the control group（ 56. 0%）,with statistical significance（ P〈0. 05）; The 1,3-year survival rate of the observation group was 92. 0% and80. 0%,respectively higher than those of the control group（ 76. 0%,54. 0%）,with statistical significance（ P〈0. 05）. Conclusions DC-CIK cells combined with chemotherapy can improve the curative rate and disease control rate in the treatment of advanced gastrointestinal cancer,and improve 1,3 year survival rate,with significantlytherapeutic effect. And it is worthy to be popularized in clinical application.

关 键 词：晚期消化道肿瘤 树突状细胞-细胞因子诱导的杀伤细胞 药物疗法 治疗结果 

分 类 号：R735[医药卫生—肿瘤]